- Waldenström Macroglobulinemia
- Melanoma
- Bladder Cancer
- Brain Cancer
- Breast Cancer
- Childhood Cancers
- Gastric Cancer
- Gynecologic Cancer
- Head & Neck Cancer
- Immunotherapy
- Kidney Cancer
- Leukemia
- Liver Cancer
- Lung Cancer
- Lymphoma Cancer
- Mesothelioma
- MPN
- MDS
- Myeloma
- Prostate Cancer
- Rare Cancers
- Sarcoma
- Skin Cancer
- Testicular Cancer
- Thyroid Cancer
Dana-Farber Leads Kadcyla ATEMPT Study in HER2-Positive Breast Cancer
Experts review an innovative study, called the ATEMPT study, which looks at adjuvant T-DM1 in women with HER2-positive breast cancer.
Experts review an innovative study, called the ATEMPT study, which looks at adjuvant T-DM1 in women with HER2-positive breast cancer.
Traditional Definition of ‘High-Risk’ in Patients With CLL and SLL Outdated, Needs to be Revisited
December 7th 2020In an interview with CURE®, Dr. Jan A. Burger discusses how the results of two phase 3 studies could help redefine what constitutes as low or high risk in patients with CLL or SLL.
Read More
To gain a better understanding of the issues faced by geriatric patients with cancer, and to determine how much of a role nutrition plays in outcomes, Dr. Grant Williams, a geriatrician oncologist and assistant professor at the University of Alabama, Birmingham, worked with colleagues to create a patient-reported assessment tool that bridges the knowledge gap in this patient population.
Read More
